Age-Related Macular Degeneration (AMD) Market - 2026-2035
Age-Related Macular Degeneration (AMD) Market reached USD 16.40 Billion in 2025 and is expected to reach USD 30.03 Billion by 2035, growing with a CAGR of 6.30% during the forecast period 2026-2035.
The Age-Related Macular Degeneration (AMD) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Age-Related Macular Degeneration (AMD) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Type
Both primary and secondary data sources have been used in the global Age-Related Macular Degeneration (AMD) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Age-Related Macular Degeneration (AMD) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Age-Related Macular Degeneration (AMD) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Type
- Dry AMD*
- Wet AMD
- Anti-VEGF Drugs*
- Ranibizumab
- Aflibercept
- Brolucizumab
- Faricimab
- Bevacizumab
- Others
- AREDS2 Supplements
- Vitamins
- Vitamin C
- Vitamin E
- Minerals
- Lutein
- Zeaxanthin
- Photodynamic Therapy
- Others
- Male*
- Female
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Age-Related Macular Degeneration (AMD) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Treatment
4.2. Snippet by Patient Type
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Product Development Activities and Market Approvals
7. RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD)
8. RESTRAINTS
8.1. High Cost of Treatment
9. OPPORTUNITIES
9.1. Market Expansion for Novel Therapeutics
9.1.1. Impact Analysis
10. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
10.1. Epidemiology
10.2. Market Leaders and Pioneers
10.3. Latest Developments and Breakthroughs
10.4. Pipeline Analysis
10.5. Regulatory and Reimbursement Landscape
10.6. Pricing Analysis
10.7. Porter’s Five Forces Analysis
10.8. Patent Analysis
10.9. SWOT Analysis
10.10. Unmet Needs and Gaps
10.11. Recommended Strategies for Market Entry and Expansion
10.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.1.2. Market Attractiveness Index, By Type
11.2. Dry AMD*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Wet AMD
12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.1.2. Market Attractiveness Index, By Treatment
12.2. Anti-VEGF Drugs*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Ranibizumab
12.2.4. Aflibercept
12.2.5. Brolucizumab
12.2.6. Faricimab
12.2.7. Bevacizumab
12.2.8. Others
12.3. AREDS2 Supplements
12.3.1. Vitamins
12.3.1.1. Vitamin C
12.3.1.2. Vitamin E
12.3.2. Minerals
12.3.3. Lutein
12.3.4. Zeaxanthin
12.3.5. Others
12.4. Photodynamic Therapy
12.5. Others
13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY PATIENT TYPE
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
13.1.2. Market Attractiveness Index, By Patient Type
13.2. Male*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Female
14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.6.1. U.S.
14.2.6.2. Canada
14.2.6.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.6.1. Germany
14.3.6.2. U.K.
14.3.6.3. France
14.3.6.4. Spain
14.3.6.5. Italy
14.3.6.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.6.1. Brazil
14.4.6.2. Argentina
14.4.6.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.6.1. China
14.5.6.2. India
14.5.6.3. Japan
14.5.6.4. South Korea
14.5.6.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15.1. Competitive Overview and Key Market Players
15.2. Market Share Analysis and Positioning Matrix
15.3. Strategic Partnerships, Mergers & Acquisitions
15.4. Key Developments in Product Portfolios and Innovations
15.5. Company Benchmarking
16. COMPANY PROFILES
Key Market Players
1. F. HOFFMANN-LA ROCHE LTD.*
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Regeneron Pharmaceuticals Inc.
1.3. Novartis AG
1.4. Apellis Pharmaceuticals, Inc.
1.5. Astellas Pharma Inc.
1.6. Biocon
1.7. Samsung Bioepis.
1.8. Bausch + Lomb.
1.9. Alcon Inc.
1.10. Nature Made(*THE LIST IS NOT EXHAUSTIVE)
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Treatment
4.2. Snippet by Patient Type
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Product Development Activities and Market Approvals
7. RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD)
8. RESTRAINTS
8.1. High Cost of Treatment
9. OPPORTUNITIES
9.1. Market Expansion for Novel Therapeutics
9.1.1. Impact Analysis
10. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
10.1. Epidemiology
10.2. Market Leaders and Pioneers
10.3. Latest Developments and Breakthroughs
10.4. Pipeline Analysis
10.5. Regulatory and Reimbursement Landscape
10.6. Pricing Analysis
10.7. Porter’s Five Forces Analysis
10.8. Patent Analysis
10.9. SWOT Analysis
10.10. Unmet Needs and Gaps
10.11. Recommended Strategies for Market Entry and Expansion
10.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.1.2. Market Attractiveness Index, By Type
11.2. Dry AMD*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Wet AMD
12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.1.2. Market Attractiveness Index, By Treatment
12.2. Anti-VEGF Drugs*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Ranibizumab
12.2.4. Aflibercept
12.2.5. Brolucizumab
12.2.6. Faricimab
12.2.7. Bevacizumab
12.2.8. Others
12.3. AREDS2 Supplements
12.3.1. Vitamins
12.3.1.1. Vitamin C
12.3.1.2. Vitamin E
12.3.2. Minerals
12.3.3. Lutein
12.3.4. Zeaxanthin
12.3.5. Others
12.4. Photodynamic Therapy
12.5. Others
13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY PATIENT TYPE
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
13.1.2. Market Attractiveness Index, By Patient Type
13.2. Male*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Female
14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.6.1. U.S.
14.2.6.2. Canada
14.2.6.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.6.1. Germany
14.3.6.2. U.K.
14.3.6.3. France
14.3.6.4. Spain
14.3.6.5. Italy
14.3.6.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.6.1. Brazil
14.4.6.2. Argentina
14.4.6.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.6.1. China
14.5.6.2. India
14.5.6.3. Japan
14.5.6.4. South Korea
14.5.6.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15.1. Competitive Overview and Key Market Players
15.2. Market Share Analysis and Positioning Matrix
15.3. Strategic Partnerships, Mergers & Acquisitions
15.4. Key Developments in Product Portfolios and Innovations
15.5. Company Benchmarking
16. COMPANY PROFILES
Key Market Players
1. F. HOFFMANN-LA ROCHE LTD.*
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Regeneron Pharmaceuticals Inc.
1.3. Novartis AG
1.4. Apellis Pharmaceuticals, Inc.
1.5. Astellas Pharma Inc.
1.6. Biocon
1.7. Samsung Bioepis.
1.8. Bausch + Lomb.
1.9. Alcon Inc.
1.10. Nature Made(*THE LIST IS NOT EXHAUSTIVE)
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
